Gene expression profiling of epithelial ovarian cancer

被引:1
作者
Sommer, Anette
Hilpert, Felix
Arnold, Norbert
机构
[1] Res Labs Schering AG, D-13342 Berlin, Germany
[2] Univ Klinikum Schleswig Holstein, Klin Gynakol & Geburtshilfe, Kiel, Germany
关键词
epithelial ovarian cancer; tumour of low malignant potential; ascites; comparative genomic hybridisation; gene expression profiling; microarray; signal transduction pathway; diagnostic marker; therapeutic target;
D O I
10.2174/138920206777304641
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Gene expression profiling using microarrays and SAGE is a widely used technology to elucidate important aspects of epithelial ovarian cancer (EOC) in order to improve the clinical management of this disease: Despite the high degree of morphological heterogeneity, epithelial ovarian cancer gene expression profiling reflects morphology and biological behaviour. Based on multiple studies, gene expression profiling results can be used to stratify the four different sub-types of EOC, namely serous papillary, mucinous, endometrioid, and clear cell carcinoma, but some overlapping gene expression was also noted. An aneuploid DNA content is a frequent phenomenon in EOC as well as in other solid tumours. However, when differential RNA expression and the DNA copy number as measured by comparative genomic hybridisation (CGH) were compared, the level of concordance was not significant in most studies. The reason for this will mostly lie in the low resolving power of currently used CGH methods and might improve with a wider access to arrayCGH. Several novel candidate markers for the early detection of EOC have been identified by gene expression profiling and examples that have been validated by ELISA on the protein level in serum from EOC patients and healthy controls are discussed. The information from gene expression profiling experiments is now being overlaid with additional information from Gene Ontology, protein-protein interaction and signal transduction pathway databases in order to discover novel therapeutic pathways and targets. Genes involved in cell cycle regulation, the extracellular matrix, and in immunological responses are relevant to epithelial ovarian cancer biology and particular genes might have the potential to be exploited as therapeutic targets for small molecules, biologicals, and immunologicals. We hope to accomplish that the scope of the review which includes a discussion of the recently published papers and the implications of the results for the clinical management of EOC is of help to researchers and clinicians in the field.
引用
收藏
页码:115 / 135
页数:21
相关论文
共 114 条
  • [1] Predicting biomarkers for ovarian cancer using gene-expression microarrays
    Adib, TR
    Henderson, S
    Perrett, C
    Hewitt, D
    Bourmpoulia, D
    Ledermann, J
    Boshoff, C
    [J]. BRITISH JOURNAL OF CANCER, 2004, 90 (03) : 686 - 692
  • [2] Gene expression microarray analysis and genome databases facilitate the characterization of a chromosome 22 derived homogenously staining region
    Arcand, SL
    Mes-Masson, AM
    Provencher, D
    Hudson, TJ
    Tonin, PN
    [J]. MOLECULAR CARCINOGENESIS, 2004, 41 (01) : 17 - 38
  • [3] Standardizing global gene expression analysis between laboratories and across platforms
    Bammler, T
    Beyer, RP
    Bhattacharya, S
    Boorman, GA
    Boyles, A
    Bradford, BU
    Bumgarner, RE
    Bushel, PR
    Chaturvedi, K
    Choi, D
    Cunningham, ML
    Dengs, S
    Dressman, HK
    Fannin, RD
    Farun, FM
    Freedman, JH
    Fry, RC
    Harper, A
    Humble, MC
    Hurban, P
    Kavanagh, TJ
    Kaufmann, WK
    Kerr, KF
    Jing, L
    Lapidus, JA
    Lasarev, MR
    Li, J
    Li, YJ
    Lobenhofer, EK
    Lu, X
    Malek, RL
    Milton, S
    Nagalla, SR
    O'Malley, JP
    Palmer, VS
    Pattee, P
    Paules, RS
    Perou, CM
    Phillips, K
    Qin, LX
    Qiu, Y
    Quigley, SD
    Rodland, M
    Rusyn, I
    Samson, LD
    Schwartz, DA
    Shi, Y
    Shin, JL
    Sieber, SO
    Slifer, S
    [J]. NATURE METHODS, 2005, 2 (05) : 351 - 356
  • [4] Bayani J, 2002, CANCER RES, V62, P3466
  • [5] Benedet JL, 2000, INT J GYNECOL OBSTET, V70, P209
  • [6] Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays
    Berchuck, A
    Iversen, ES
    Lancaster, JM
    Dressman, HK
    West, M
    Nevins, JR
    Marks, JR
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2004, 190 (04) : 910 - 922
  • [7] Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers
    Berchuck, A
    Iversen, ES
    Lancaster, JM
    Pittman, J
    Luo, JQ
    Lee, P
    Murphy, S
    Dressman, HK
    Febbo, PG
    West, M
    Nevins, JR
    Marks, JR
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (10) : 3686 - 3696
  • [8] High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer
    Bernardini, M
    Lee, CH
    Beheshti, B
    Prasad, M
    Albert, M
    Marrano, P
    Begley, H
    Shaw, P
    Covens, A
    Murphy, J
    Rosen, B
    Minkin, S
    Squire, JA
    Macgregor, PF
    [J]. NEOPLASIA, 2005, 7 (06): : 603 - 613
  • [9] Re: Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers
    Bertucci, F
    Eisinger, F
    Tagett, R
    Sobol, H
    Birnbaum, D
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (19) : 1506 - 1507
  • [10] Oncogenic pathway signatures in human cancers as a guide to targeted therapies
    Bild, AH
    Yao, G
    Chang, JT
    Wang, QL
    Potti, A
    Chasse, D
    Joshi, MB
    Harpole, D
    Lancaster, JM
    Berchuck, A
    Olson, JA
    Marks, JR
    Dressman, HK
    West, M
    Nevins, JR
    [J]. NATURE, 2006, 439 (7074) : 353 - 357